BioNTech (NASDAQ:BNTX) Stock Price Up 2.9% - Should You Buy?

BioNTech SE (NASDAQ:BNTX - Get Free Report) shot up 2.9% during mid-day trading on Tuesday . The stock traded as high as $117.98 and last traded at $117.49. 136,530 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 806,539 shares. The stock had previously closed at $114.22.

Analysts Set New Price Targets

BNTX has been the subject of several recent analyst reports. Berenberg Bank assumed coverage on BioNTech in a research note on Tuesday, November 19th. They set a "buy" rating and a $130.00 target price on the stock. Canaccord Genuity Group increased their target price on BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research note on Wednesday, November 27th. Jefferies Financial Group upgraded shares of BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. HSBC raised their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and an average price target of $140.76.

BioNTech Stock Up 2.8 %

The business's fifty day moving average price is $113.66 and its two-hundred day moving average price is $100.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $27.91 billion, a P/E ratio of -55.90 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the firm earned $0.73 earnings per share. BioNTech's revenue was up 38.9% compared to the same quarter last year. Equities analysts expect that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently modified their holdings of BNTX. FMR LLC raised its stake in BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after acquiring an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC purchased a new position in shares of BioNTech in the third quarter worth about $59,485,000. Candriam S.C.A. lifted its holdings in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. boosted its position in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the last quarter. Finally, Braidwell LP acquired a new position in BioNTech in the 3rd quarter worth approximately $29,425,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.